The FDA has received the required submissions from Cetero for only 53 of the 100 drugs, while an FDA email chain, released by Propublica.org, notes that some new studies have not yet been submitted to the FDA. Although the FDA has set two deadlines for Cetero's resubmission of clinical trial repeats, analyses, or audits, some of the deadlines have been ignored, without consequence.
The FDA has kept the identities of all of these drugs secret. Comparatively, the European Medicines Agency (EMA) has withdrawn seven drugs tested by Cetero from the European market. Furthermore, the EMA publishes publicly available records of drugs undergoing scrutiny, so that doctors, patients, and researchers can maintain awareness of any prescription medicine safety updates.
FDA Secretly Retests 100 Different Drugs After Testing Company Admits its Work was All Fraudulent